Reflecting on type 2 diabetes prevention: More questions than answers!

Diabetes, Obesity and Metabolism

Volumn 9, Issue SUPPL.1, 2007, Pages 3-11

  Rosenstock, Julio ^a  

^a DALLAS DIABETES AND ENDOCRINE CENTER AT MEDICAL CITY   (United States)

Author keywords

American Diabetes Association Consensus Statement; Impaired fasting glucose; Impaired glucose tolerance; Lifestyle changes; Prediabetes; Type 2 diabetes mellitus epidemic

Indexed keywords

ACARBOSE; DIPEPTIDYL PEPTIDASE IV INHIBITOR; GLUCOSE; HEMOGLOBIN A1C; HIGH DENSITY LIPOPROTEIN CHOLESTEROL; METFORMIN; PLACEBO; RAMIPRIL; ROSIGLITAZONE; TETRAHYDROLIPSTATIN; TRIACYLGLYCEROL; TROGLITAZONE; VILDAGLIPTIN;

BEHAVIOR CHANGE; BLOOD PRESSURE REGULATION; CARDIOVASCULAR DISEASE; CAROTID ARTERY ANOMALY; CLINICAL TRIAL; CONGESTIVE HEART FAILURE; CONSENSUS DEVELOPMENT; DIABETIC ANGIOPATHY; DIET RESTRICTION; DIET THERAPY; DISEASE COURSE; DRUG EFFICACY; DRUG FATALITY; DRUG TOLERABILITY; ECONOMIC ASPECT; EPIDEMIC; EXERCISE; FAMILY HISTORY; GASTROINTESTINAL DISEASE; GLYCEMIC CONTROL; HEALTH CARE ORGANIZATION; HEART INFARCTION; HUMAN; HYPERGLYCEMIA; HYPERTENSION; HYPOGLYCEMIA; IMPAIRED GLUCOSE TOLERANCE; LIFESTYLE MODIFICATION; LIVER DYSFUNCTION; MEDICAL DECISION MAKING; MORTALITY; NON INSULIN DEPENDENT DIABETES MELLITUS; OBESITY; PANCREAS ISLET BETA CELL; PATIENT CARE; PATIENT COUNSELING; PATIENT MONITORING; PATIENT SELECTION; PHYSICAL ACTIVITY; PUBLIC HEALTH PROBLEM; REVIEW; RISK FACTOR; RISK REDUCTION; SIDE EFFECT; WEIGHT CHANGE; WEIGHT GAIN; WEIGHT REDUCTION;

EID: 34548809173     PISSN: 14628902     EISSN: 14631326     Source Type: Journal    
DOI: 10.1111/j.1463-1326.2007.00768.x     Document Type: Review

References (27)

1. Wild S, Roglic G, Green A, Sicree R, King H. Global prevalence of diabetes: Estimates for the year 2000 and projections for 2003. Diabetes Care 2004; 27: 1047-1053.
2. Nathan DM, Davidson MB, DeFronzo RA et al. Consensus statement: Impaired fasting glucose and impaired glucose tolerance: Implications for care. Diabetes Care 2007; 30: 753-759.
3. Rijkelijkhuizen JM, Nijpels G, Heine RJ, Bouter LM, Stehouwer CDA, Dekker JM. High risk of cardiovascular mortality in individuals with impaired fasting glucose is explained by conversion to diabetes: The HOORN study. Diabetes Care 2007; 30: 332-336.
4. Abdul-Ghani MA, Jenkinson CP, Richardson DK et al. Insulin secretion and action in subjects with impaired fasting glucose and impaired glucose tolerance: Results from the veterans administration genetic epidemiology study. Diabetes 2006; 55: 1430-1435.
5. Knowler WC, Barrett-Connor E, Fowler SE et al. Reduction in the incidence of type 2 diabetes with lifestyle intervention or metformin. N Engl J Med 2002; 346: 393-403.
6. Ratner R, Goldberg R, Haffner S et al. Impact of intensive lifestyle and metformin therapy on cardiovascular disease risk factors in the Diabetes Prevention Program. Diabetes Care 2005; 28: 888-894.
7. Gerstein HC, Yusuf S, Bosch J et al. Effect of rosiglitazone on the frequency of diabetes in patients with impaired glucose tolerance or impaired fasting glucose: A randomized controlled trial. Lancet 2006; 368: 1096-1105.
8. Nissen SE, Wolski K. Effect of rosiglitazone on the risk of myocardial infarction and death from cardiovascular causes. N Engl J Med 2007; 356: 2457-2471.
9. Buchanan TA, Xiang AH, Peters RK et al. Preservation of pancreatic β-cell function and prevention of type 2 diabetes by pharmacologic treatment of insulin resistance in high-risk Hispanic women. Diabetes 2002; 51: 2796-2803.
10. Chiasson JL, Josse RG, Gomis R et al. Acarbose for prevention of type 2 diabetes mellitus: The STOP-NIDDM randomized trial. Lancet 2002; 359: 2072-2077.
11. Chiasson JL, Josse RG, Gomis R et al. Acarbose treatment and the risk of cardiovascular disease and hypertension in patients with impaired glucose tolerance: The STOP-NIDDM trial. JAMA 2003; 290: 486-494.
12. Gerstein HC. Point: If it is important to prevent type 2 diabetes, it is important to consider all proven therapies within a comprehensive approach. Diabetes Care 2007; 30: 432-434 (Editorial).
13. Tuomilehto J, Lindström J, Eriksson JG et al. Prevention of type 2 diabetes mellitus by changes in lifestyle among subjects with impaired glucose tolerance. N Engl J Med 2001; 344: 1343-1350.
14. Pan XR, Li GW, Hu YH et al. Effects of diet and exercise in preventing NIDDM in people with impaired glucose tolerance. The Da Qing IGT and Diabetes Study. Diabetes Care 1997; 20: 537-544.
15. Kosaka K, Noda M, Kuzuya T. Prevention of type 2 diabetes by lifestyle intervention: A Japanese trial in IGT males. Diabetes Res Clin Pract 2005; 67: 152-162.
16. Ramachandran A, Snehalatha C, Mary S, Mukesh B, Bhaskar AD, Vijay V. The Indian Diabetes Prevention Programme shows that lifestyle modification and metformin prevent type 2 diabetes in Asian Indian subjects with impaired glucose tolerance (IDPP-1). Diabetologia 2006; 49: 289-297.
17. Torgerson JS, Hauptman J, Boldrin MN, Sjostrom L. XENical in the Prevention of Diabetes in Obese Subjects (XENDOS) Study: A randomized study of orlistat as an adjunct to lifestyle changes for the prevention of type 2 diabetes in obese patients. Diabetes Care 2004; 27: 155-161.
18. Diabetes Prevention Program Research Group. Prevention of type 2 diabetes with troglitazone in the Diabetes Prevention Program. Diabetes 2005; 54: 1150-1156.
19. Lindström J, Ilanne-Parikka P, Peltonen M et al. Sustained reduction in the incidence of type 2 diabetes by lifestyle intervention: follow-up of the Finnish Diabetes Prevention Study. Lancet 2006; 368: 1673-1679.
20. Holman RR, Bosch J, Yusuf S, Gerstein H. DREAM trial washout results. Diabetic Medicine 2006; 23 (Suppl. 4): 635 (Abstract).
21. Kahn SE, Haffner SM, Heise MA et al. Glycemic durability of rosiglitazone, metformin, or glyburide monotherapy. N Engl J Med 2006; 355: 2427-2443.
22. Duttaroy A, Voelker F, Merriam K. The DDP-4 inhibitor vildagliptin increases pancreatic beta cell neogenesis and decreases apoptosis. Diabetes 2005; 54: A141 (Abstract).
23. Mu J, Woods J, Zhou YP et al. Chronic inhibition of dipeptidyl peptidase-4 with a sitagliptin analog preserves pancreatic β-cell mass and function in a rodent model of type 2 diabetes. Diabetes 2006; 55: 1695-1704.
24. Foley JE, Ligueros-Saylan M, Watson CA et al. Differential effects of vildagliptin on islet function in patients with type 2 diabetes receiving no additional agent or concomitant metformin. Diabetologia 2006; 49 (Suppl. 1): 397 (Abstract).
25. Drucker DJ, Nauck MA. The incretin system: Glucagon-like peptide-1 receptor agonists and dipeptidyl peptidase-4 inhibitors in type 2 diabetes. Lancet 2006; 368: 1696-1705.
26. Rosenstock J, Baron MA, Dejager S et al. Comparison of vildagliptin and rosiglitazone monotherapy in patients with type 2 diabetes: A 24-week, double-blind, randomized trial. Diabetes Care 2007; 30: 217-223.
27. Rosenstock J, Zinman B. Dipeptidyl peptidase-4 inhibitors and the management of type 2 diabetes mellitus. Curr Opin Endocrinol Diabetes Obes 2007; 14: 98-107.